ライフサイエンスコーパス: isoxazole

1 tituents at the 3, 4, and 5 positions of the isoxazole.

2 1,3-diketone moiety masked in the form of an isoxazole.

3 odium vinylcarbenoids across the N-O bond of isoxazoles.

4 of aryl iodides affords 3,4,5-trisubstituted isoxazoles.

5 st-8-en-3-one (10) give predominantly [3,2-c]isoxazoles.

6 n be synthesized in a one-pot procedure from isoxazoles.

7 thiooxoaminothiazoles, and pyrazole-pyrrole-isoxazoles.

8 f the desired 4-alkenyl-3,4,5-trisubstituted isoxazoles.

9 D4 affinity, based on crystal structures of isoxazoles (29 and 30) and on a conformationally constra

10 -methyl-1H-benzotriazole 5, 3-methyl-benzo[d]isoxazole 3, and 3-methyl-[1,2,4]triazolo[4,3-a]pyridine

11 3,5-bis(4-amidinophenyl)isoxazole (3)-an analogue of 2,5-bis(4-amidinophenyl)fur

12 ely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 7a and N-(pyridin-2-yl)-5-(2-(p-

13 yridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 8a, were found to show high inhi

14 l- N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[ d]isoxazole-3-carboxamide derivatives as novel potent Myco

15 potent 5-(2-methylbenzothiazol-5-yloxymethyl)isoxazole-3-carboxamide derivatives, which proved to be

16 8-bis(trifluoromethyl)quinolin-4-yloxymethyl)isoxazole-3-carboxylic acid ethyl ester (compound 3) wit

17 ough 5-HT(2A) and/or 5-HT(2C) receptors, the isoxazoles 3d and 4d constitute interesting leads for fu

18 H) acetates into alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates is described.

19 activation of alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate/kainate (AMPA/KA) and NMDA recept

20 domain of the alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor subunit GLuR-

21 necrotically in an -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor-dependent man

22 C termini of alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptors in vitro and

23 artic acid or alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA)-subtype glutamate rece

24 nate, and tritiated amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA).

25 nate, and tritiated amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA).

26 AMPAR (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptor) is an ion channel i

27 postsynaptic alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs) prevents L

28 mpal neurons, alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid subtype glutamate receptor (A

29 ate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) and kainate receptors; criti

30 following AMPA (DL-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid) receptor activation.

31 for agonist (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid)-initiated rapid proteolytic

32 The isoxazol-3-one tautomer of the bicyclic isoxazole, 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-

33 Isoxazole 6d demonstrated impressive efficacy when admin

34 evious work with a synthetic small molecule, isoxazole 9 (Isx-9), highlighted its neuronal-differenti

35 Systemic treatment with the drug Isoxazole-9 (a synthetic small molecule known to modulat

36 Isoxazole-9 modulated neurogenesis, neuronal activation

37 injury, and treatment of dermal wounds with isoxazole accelerates wound closure and suppresses the i

38 itor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) inhibited huM

39 d to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an inhibitor

40 y of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an orally bi

41 and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1).

42 nist (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester considerably attenuat

43 O-1 ((S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester)," significantly inhi

44 nctionality of UPOC methyl ester with a free isoxazole acid using HBTU or alternatively an isoxazole

45 nd the enyne gave the rare 3,4-disubstituted isoxazole adduct under kinetic reaction conditions.

46 d N,N-dialkylamino-3-aryl/alkyl-4-(2-R-vinyl)isoxazoles afford 2-aryl/alkyl-5-aryl/alkyl/methoxycarbo

47 urine BIIB021, and the resorcinylic pyrazole/isoxazole amide compounds VER-49009, VER-50589, and NVP-

48 operties of NVP-AUY922, a novel resorcinylic isoxazole amide heat shock protein 90 (HSP90) inhibitor.

49 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) glutamate receptors across the lifespan

50 tion of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA)-type glutamate receptor has recently be

51 A library of isoxazole and 1,2,4-oxadiazole-containing diheterocyclic

52 The terminal isoxazole and benzyl rings bind into distinct relatively

53 parameters, as demonstrated for a library of isoxazole and pyrazole derivatives.

54 ways under VNS conditions, one leading to an isoxazole and the other resulting in the formal cyclopro

55 tituted isoxazole was then conducted with 56 isoxazole and triazole derivatives prepared using "click

56 the synthesis and evaluation of a series of isoxazoles and other monocyclic compounds.

57 ltered to a number of different groups, with isoxazoles and pyrimidines showing improved affinities.

58 ccess to stable MIDA boronate-functionalized isoxazoles and triazoles and their subsequent efficient

59 ium, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (+/-)-epibatidine, resulted in concentrat

60 thiophene, furan, pyridine, indole, oxazole, isoxazole, and benzoxazole, are effective in this chemis

61 pyridines, imidazoles, oxazoles, thiazoles, isoxazoles, and pyrazoles.

62 chromenes to o-hydroxybenzylated pyrazoles, isoxazoles, and pyridines has been demonstrated.

63 which the central furan ring is replaced by isoxazole-and 42 novel analogues were prepared by two ge

64 3,5-Disubstituted isoxazoles are obtained in good yields by a convenient o

65 A variety of trisubstituted isoxazoles are prepared in moderate to excellent yields.

66 of cell or tissue lysates to a biotinylated isoxazole (b-isox) chemical precipitated hundreds of RNA

67 s and human cell lysates with a biotinylated isoxazole (b-isox) chemical.

68 and SAR of a potent and selective series of isoxazole based full agonists of S1P1.

69 An isoxazole-based alkylating agent was developed to select

70 The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads fo

71 dy, we have continued our efforts to develop isoxazole-based anti-TB compounds by applying rational d

72 Other isoxazole-based pharmaceuticals are probably also metabo

73 t both compounds 5 and 10 do not give [3,2-c]isoxazoles but rather afford regioselectively [2,3-d]iso

74 ral elaborations of these highly substituted isoxazoles by SN Ar reactions and hydrogenolysis allows

75 r of uracil polyoxin C (UPOC) with activated isoxazole carboxylic acids.

76 A phenyl dimethyl isoxazole chemotype resulting from a focused fragment sc

77 5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI) has been identified as a PAM selective

78 proven general with a range of carbenoid and isoxazole components and represents a unique disconnecti

79 Starting from compound 1, an isoxazole compound with potent AM2-S31N channel blockage

80 y to investigate the effects of one of these isoxazole compounds, WJ352, on the conformation of the S

81 uinoline-based anti-TB compounds, bearing an isoxazole containing side-chain.

82 lore the structure-activity relationships of isoxazole-containing AM2-S31N inhibitors.

83 A range of isoxazole-containing amino acids was synthesized that di

84 Affinities of the isoxazole-containing peptides are comparable to those of

85 o(-bromo or -methyl)furan-2-yl groups on the isoxazole core was essential for their selectivity towar

86 ble, and the thermodynamic 3,5-disubstituted isoxazole could be obtained by isomerization of its 3,4-

87 caffold Hsp90 inhibitor CNF2024/BIIB021, the isoxazole derivative VER-52296/NVP-AUY922, and the carba

88 (PM226)], a selective and potent CB2 agonist isoxazole derivative, was tested in the acute phase of T

89 The 43 isoxazole derivatives were assayed against Trypanosoma b

90 lar library containing over 40 cycloalkane[d]isoxazole derivatives.

91 1600-fold and only leads to formation of the isoxazole end product (the result of the transaminase pa

92 y, a new series of nAChR ligands based on an isoxazole-ether scaffold have been designed and synthesi

93 Cycloalkane[d]isoxazoles form new core structures that interact with t

94 rocyclic framework (the anthranil or benzo[c]isoxazole framework) is formed as the result of diversio

95 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate receptor subunit GluR2 in the nucle

96 Following the discovery that a 3-amino-isoxazole group displays significantly improved metaboli

97 comparison to its 5-regioisomer, the 3-amino-isoxazole group was combined with the optimal 2'-substit

98 group and the carbon atom of the carboxyl or isoxazole group.

99 do-dig cyclization-alkenylation synthesis of isoxazoles has been developed.

100 es but rather afford regioselectively [2,3-d]isoxazoles in good yields.

101 electrophiles, furnished the functionalized isoxazoles in good yields.

102 yzed reactions to yield 3,4,5-trisubstituted isoxazoles, including valdecoxib.

103 ed to the identification of 3-amino benzo[ d]isoxazoles, incorporating a N, N'-diphenyl urea moiety a

104 The photochemistry of matrix-isolated isoxazole, induced by narrowband tunable UV-light, was i

105 Isoxazole is chemically attached to Si(111)-7 x 7 throug

106 ied a family of neurogenic 3,5-disubstituted isoxazoles (Isx) that increased expression of neurogenic

107 A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric re

108 phenyl ring as well as the 5-position of the isoxazole moiety may allow for the development of more p

109 , we reported on a series of isoxazoline and isoxazole monobasic noncovalent inhibitors of factor Xa

110 ndensation with benzamidoxime gave the final isoxazole-oxadiazole diheterocyclic product in good yiel

111 lecules containing two different heteroatoms isoxazole, oxazole, and thiazole on Si(111)-7 x 7 was st

112 ecules containing two different heteroatoms (isoxazole, oxazole, and thiazole) and of the aromatic mo

113 for the first time as an intermediate in the isoxazole-oxazole photoisomerization.

114 th hydrolytically stable, fused isoxazolone, isoxazole, oxazolone, or cyano substituents on the aroma

115 soxazole acid using HBTU or alternatively an isoxazole pentafluorophenyl ester.

116 stematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen re

117 indings, a detailed mechanistic proposal for isoxazole photochemistry is presented.

118 The isoxazole photoreaction starts to occur upon irradiation

119 oxygen on the electrophilic amine to produce isoxazole products, as compared to the previous reportsa

120 tors [i.e., alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and/or kainate (KA) receptor

121 H]-MK-801, [3H]-2-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) or [3H]-kainate.

122 changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor distribution in liv

123 type of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor in mice disrupts th

124 king of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluA1 and

125 nalysis for alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluR2 and

126 mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors (AMPARs) and is Ca

127 by NMDA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors in hippocampal pyr

128 hyperactive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors.

129 utamate and alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate (AMPA)) and a partial agonist (kain

130 family, namely, a-amino-3-hydroxy-S-methyl-4-isoxazole propionate (AMPA), kainate, and N-methyl-d-asp

131 erations to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-type glutamate receptors cau

132 1, NR2A/B), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (GluR1, GluR2/3, GluR4) and low aff

133 ate binding alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate and kainate subtypes of the ionotro

134 ion of the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionate receptor (AMPAR) subunit 1 (GluR1),

135 ha and the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionate receptor subunit GluR1.

136 plasticity, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors (AMPA-Rs) with an electro

137 ts of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) glutamate receptors in the nucleus

138 The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor is the predominant mediat

139 it of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor mediates two dynamic chan

140 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, in cerebral cortex, und

141 olution the alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate-bound form of this mutant exists pr

142 ted against alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-induced or to a lesser extent N-met

143 rtate-type, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-type, and metabotropic-type glutama

144 e glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptor antagonist CNQX (0

145 n M2 of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptor GluR1 that specify

146 kade of two alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptor subunit 1 (GluR1)

147 uRs) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate subtype display lower perme

148 alpha-Amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors mediate excitatory

149 ters of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors or the postsynapti

150 In alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors, RNA editing and a

151 motoneuron alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors.

152 increased alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) throughput.

153 receptors, alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), and N-methyl-d-aspartic aci

154 regulated alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)-induced GluR1 and GluR2 inte

155 NMDAR) and alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor (AMPAR) are ionotropic glu

156 reases the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor (AMPAR)-mediated contribut

157 /NR2b) and alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPA-R) (GluR1/GluR2) se

158 ediated by alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) and N-methyl-d-a

159 -permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) in the lateral a

160 osition of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) is an important

161 mplex with alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs), the major excit

162 containing alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (GluR1-AMPARs) are implic

163 -permeable, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors.

164 to control alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate sensitivity of these kainate recept

165 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate) recep-tors desensitize rapidly and

166 tion, AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate)-preferring and kainate (KA)-prefer

167 subunits of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-preferring, kainate-preferring, and

168 esponses of alpha-amino3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptors in a numbe

169 , acting at alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) -selective and kainate-s

170 ontogeny of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate (KA) glutama

171 tio between alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-methyl-D-aspartate

172 revealed that alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid (AMPA) and N-methyl-D-aspartate

173 VGCCs), the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) class of glutamate recep

174 competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor antag

175 ceptors for alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) in the nucleus accumbens

176 ocked by the alpha-amino-3-hydoxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist 6-ni

177 ansmembrane alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor regulatory prot

178 full-length alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionic acid (AMPA) receptor structure (1).

179 specific to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor subunits (i.e.

180 ulations of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-active and inac

181 cloning of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-binding protein

182 nterneurone alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-mediated conduc

183 r 3 (GluR3) alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (WT GluR3) and

184 e number of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are proportion

185 by blocking alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors impaired both

186 ribution of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors to the control

187 Kainate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors were initially

188 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, the two major

189 smission by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.

190 ors of the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid (AMPA) subtype and has been lin

191 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtypes of glutamate re

192 morphology, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) to N-methyl-D-aspartate

193 pression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate, and N-methyl-D

194 ediated via alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-sensitive glutamate rece

195 ture of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-sensitive, homotetrameri

196 lization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

197 hibition of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

198 alpha-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

199 Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

200 A)-type and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

201 alate), and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA).

202 asticity of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate recept

203 Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate recept

204 1 and GluA2 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) and GluN1 N-me

205 ly modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) clustering and

206 (NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) properties to

207 tion of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) subunit, GluR1

208 hippocampal alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) trafficking, a

209 tagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR).

210 cts require alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor activation and are blo

211 a glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonist.

212 but not the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluR2, were co

213 s of AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor)-mediated currents fol

214 -permeable) alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPAR) in the hippoc

215 The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) are glutamat

216 -containing alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) in spines.

217 )-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) in the hippo

218 , including alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), are believe

219 ostsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs).

220 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs).

221 )-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (CP-AMPARs).

222 NMDAR but not alpha-amino-3-hydroxy-methyl-4-isoxazole propionic acid receptors was also increased.

223 of AMPARs (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors).

224 Glutamate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with cyclothiazide, and thapsig

225 tor agonist alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with high affinity.

226 ffinity AMPA (alpha-amino-3-hydroxy-5-methyl isoxazole propionic acid) and kainate glutamate receptor

227 d rat AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptor subtypes

228 ate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptors.

229 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) glutamate receptor (AMPAR).

230 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor subunit GluA1.

231 o of AMPA (alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid) receptor- to NMDA (N-methyl-d-

232 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors (AMPARs), activated

233 on of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, a subtype of glutam

234 aptic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, thereby strengtheni

235 ce of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors.

236 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors.

237 nists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), kainate (a structural analogu

238 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate),

239 tion of AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid)-receptor-mediated currents at

240 uced an AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid)-receptor-mediated increase in

241 of an AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-subtype iGluR in explicit wate

242 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-subtype ionotropic glutamate r

243 ereas AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate receptor subunits were

244 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate receptors alone or by

245 unit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptor, Ser94

246 lization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors (AMPAR

247 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid.

248 signals to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid.

249 intra-NASh alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/N-methyl-D-aspartate receptor t

250 receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; AMPA-Rs) purified from rat bra

251 delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic-type receptors (AMPARs) to synapses,

252 The (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole) propionic acid (AMPA) receptor discriminates

253 nists on (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole) propionic acid (AMPA) receptors but neverthel

254 The (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole)propionic acid (AMPA)-subtype glutamate recept

255 NR2A/B) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) (GluR1 and GluR2) subuni

256 tor and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor in the dorsal,

257 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors is implicated

258 cluding the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-type glutamate receptor.

259 ferences in alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunit expres

260 gulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunits in th

261 function of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, and, more recently,

262 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors.

263 partate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) and metabotropic glutamate (mG

264 icostriatal alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid-type glutamate receptor-mediate

265 [3H]KA, and alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionate (AMPA) receptors were labeled with

266 ng to NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-proprionate (AMPA), and kainate receptors in b

267 unit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor failed to reve

268 n inhibited alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor-mediated synap

269 tion of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA)/KA receptor agonist KA

270 onformation generally seen with the pyrazole/isoxazole-resorcinol class of inhibitors.

271 ituted 1,2,3-triazoles and 3,4-disubstituted isoxazoles, respectively.

272 This study revealed that while the isoxazole ring can be replaced by a triazole system, the

273 hilic side chains at the C-5 position of the isoxazole ring have been prepared.

274 ion reaction was developed, allowing for the isoxazole ring opening and global deprotection to be ach

275 its active metabolite teriflunomide through isoxazole ring opening has been monitored in vitro using

276 ed aldehyde, aminocarbonyl, cyano groups, or isoxazole ring) with thiol salts were investigated.

277 We also identify an isoxazole ring-containing small molecule, previously sho

278 which have no substituent on the 2beta-(1,2-isoxazole) ring, all compounds were selective for the DA

279 tion of "atom replacement" mimetics in which isoxazole rings linked by thioethers mimic the alternati

280 carboxylic acid moiety onto a trisubstituted isoxazole scaffold.

281 Isoxazole stimulates myofibroblast differentiation via i

282 ime in the presence of bleach) to afford the isoxazole-substituted carboxylic acid methyl ester.

283 N-(2,6-Diisopropylphenyl)-N'-tetrazole or isoxazole-substituted heterocyclic ureas proved optimal.

284 The ED(50) values for 2beta-(1,2-isoxazoles) that caused locomotor stimulation ranged fro

285 aldehydes are converted to fused tetracyclic isoxazoles through a synthetic sequence incorporating su

286 the domino isomerization, transformation of isoxazole to 2H-azirine, which is compatible with Ph3PAu

287 lieu of an alkene leads to the formation of isoxazole under identical reaction conditions.

288 = 221 nm, in addition to this decomposition, isoxazole was also found to isomerize into several produ

289 ationship analysis of this 3,5-disubstituted isoxazole was then conducted with 56 isoxazole and triaz

290 ds based on amantadine- and aryl-substituted isoxazole were discovered to inhibit the S31N channel ac

291 d in two steps from the corresponding [2,3-d]isoxazole, which is interesting from the perspective of

292 carboxylic acids (imidazo[1,2-a]pyridine and isoxazole) with aryl halides.

293 lucuronidated less than previously described isoxazoles, yielding higher drug levels in human cancer